journal article·2021-01Open access

Injectable oxygenation therapeutics: evaluating the oxygen delivery efficacy of artificial oxygen carriers and kosmotropes in vitro

Meghna S. Jayaraman, Kaitlin Graham, Evan C. Unger

Abstract

The aim of this paper was to utilise an existing in vitro setup to quantify the oxygen offloading capabilities of two different subsets of injectable oxygenation therapeutics: (1) artificial oxygen carriers (AOCs), which bind or dissolve oxygen and act as transport vectors, and (2) kosmotropes, which increase water hydrogen bonding and thereby decrease the resistance to oxygen movement caused by the blood plasma. Dodecafluoropentane emulsion (DDFPe) was chosen to represent the AOC subset while trans sodium crocetinate (TSC) was selected to represent the kosmotrope subset. PEG-Telomer-B (PTB), the surfactant utilised to encapsulate DDFP in emulsion form, was also tested to determine whether it affected the oxygen transport ability of DDFPe. The in vitro set-up was used to simulate a semi closed-loop circulatory system, in which oxygen could be delivered from the lungs to hypoxic tissues. Results of this study showed that (1) 0.5 ml of a PFC outperformed 6.25 ml of a kosmotrope in a controlled, in vitro setting and (2) that PTB and sucrose do not contribute to the overall oxygen transportation efficacy of DDFPe. These results could be therapeutically beneficial to ongoing and future pre-clinical and clinical studies involving various oxygenation agents.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hemoglobin structure and function · Traumatic Brain Injury and Neurovascular Disturbances · Cerebrospinal fluid and hydrocephalus

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NuvOx Pharma, LLC, Tucson, AZ, USA

References (28)

Show source-provided references
1. 10.1152/japplphysiol.90995.200810.1152/japplphysiol.90995.2008 ↗
2. 10.1097/SHK.000000000000106010.1097/SHK.0000000000001060 ↗
3. 10.1016/j.brainres.2016.01.01210.1016/j.brainres.2016.01.012 ↗
4. 10.1080/1073119060118825710.1080/10731190601188257 ↗
5. 10.2174/1874205X0140801002710.2174/1874205X01408010027 ↗
6. 10.1016/j.jvir.2011.10.00110.1016/j.jvir.2011.10.001 ↗
7. 10.1111/j.1525-1594.2008.00692.x10.1111/j.1525-1594.2008.00692.x ↗
8. 10.1258/000714299190225910.1258/0007142991902259 ↗
9. 10.1081/BIO-20004665910.1081/BIO-200046659 ↗
10. Spiess BD. Basic mechanisms of gas transport and past research using perfluorocarbons. Diving Hyperb Med. 2010;40(1):23–28.
11. 10.1351/pac19825412238310.1351/pac198254122383 ↗
12. 10.1080/21691401.2019.157788210.1080/21691401.2019.1577882 ↗
13. 10.1080/1073119090304319210.1080/10731190903043192 ↗
14. 10.1007/978-3-319-45345-3_2610.1007/978-3-319-45345-3_26 ↗
15. 10.1021/acs.jpcb.7b1278210.1021/acs.jpcb.7b12782 ↗
16. 10.1016/0034-5687(85)90020-910.1016/0034-5687(85)90020-9 ↗
17. 10.1113/jphysiol.1981.sp01377310.1113/jphysiol.1981.sp013773 ↗
18. 10.3171/2016.3.JNS15269310.3171/2016.3.JNS152693 ↗
19. Johnson JL Unger E. 2014. Buffered oxygen therapeutic. United States Patent 8 822 549 September 2 2014.
20. Gainer JL. 1996. Trans-sodium crocetinate methods of making and methods of use thereof. United States Patent 6 060 511.
21. 10.1016/j.jvir.2019.04.02010.1016/j.jvir.2019.04.020 ↗
22. 10.1186/cc96810.1186/cc968 ↗
23. 10.4199/C00029ED1V01Y201103ISP01710.4199/C00029ED1V01Y201103ISP017 ↗
24. 10.1517/13543784.17.6.91710.1517/13543784.17.6.917 ↗
25. 10.1093/bjaed/mkw01210.1093/bjaed/mkw012 ↗
26. Popel AS. Theory of oxygen transport to tissue. Crit Rev Biomed Eng. 1989;17(3):257–321.
27. 10.1111/bjh.1393710.1111/bjh.13937 ↗
28. 10.1081/HEM-12003591910.1081/HEM-120035919 ↗